FDA Ulcerative Colitis Guidance: 'Ideal' Vision Vs. Practical Interim Approach
Executive Summary
Agency favors assessments of signs/symptoms and endoscopy findings using well-defined and reliable patient- and clinician-reported outcomes instruments; since these don't exist, FDA will allow tweaking of existing assessment tools in the interim.